Metacrine Inc.
Metacrine Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Metacrine Inc..
Metacrine Inc. is a company.
Key people at Metacrine Inc..
Key people at Metacrine Inc..
Metacrine, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal (GI) diseases.[1][2][3] It builds a pipeline targeting the farnesoid X receptor (FXR), a key modulator of liver and GI conditions, with lead candidates including MET642 (completed Phase I for ulcerative colitis) and MET409.[1][3][4] The company serves patients suffering from disorders like ulcerative colitis and liver diseases, addressing unmet needs through oral medications with improved therapeutic profiles via a proprietary FXR platform and unique chemical scaffold demonstrated in clinical trials.[2][4]
Incorporated in 2014 and headquartered in San Diego, California (with references to San Ramon), Metacrine remains in early clinical development without approved products, emphasizing growth through pipeline advancement.[1][2]
Metacrine, Inc. was incorporated in 2014 as a clinical-stage biopharmaceutical venture.[1] Limited public details exist on specific founders or their backgrounds, but the company emerged to leverage a proprietary FXR platform for liver and GI therapies, capitalizing on the receptor's central role in disease modulation.[2][3] Early pivotal moments include advancing MET642 through Phase I trials for ulcerative colitis and developing MET409, establishing initial clinical validation of its chemical scaffold's therapeutic potential.[1][3][4]
Metacrine rides the trend of precision biopharma targeting nuclear receptors like FXR to treat chronic GI and liver diseases, amid rising prevalence of conditions like ulcerative colitis and non-alcoholic steatohepatitis (NASH).[2][3] Timing aligns with advances in oral small-molecule therapies, where improved safety profiles from novel scaffolds enable better patient compliance over injectables.[2][4] Market forces favoring it include growing demand for GI treatments and FXR agonists, influenced by clinical successes in related spaces, positioning Metacrine to contribute to the ecosystem through pipeline innovations despite its early-stage status.[1][3]
Metacrine's next milestones hinge on Phase II data for MET642 in ulcerative colitis and potential expansion of its FXR pipeline, with trends in GI biologics and oral therapies shaping progress.[1][4] Influence may evolve via partnerships or acquisitions, given its $0.58 share price as of mid-2023 and focus on differentiated assets, potentially amplifying impact in liver/GI biopharma if trials succeed.[5] This positions the clinical-stage pioneer as a watchlist contender in unmet disease innovation, echoing its founding mission to transform patient therapies.[2]
